Metrion Biosciences Ltd. and The KCNC1 Foundation have established a collaboration to progress a hit identification research project for small-molecule modulators of the potassium ion channel Kv3.1, targeting KCNC1-related disorders.
Tetra Bio-Pharma Inc. has reported results from a study of ARDS-003 (onternabez) combined with favipiravir against acute respiratory distress syndrome (ARDS), sepsis and COVID-19 through PREPAiRE, an artificial intelligence (AI)-powered platform which integrates target identification, validation, lead discovery optimization, drug synthesis and preclinical testing.
Pfizer Inc. and Clear Creek Bio Inc. have entered into a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19.
The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its partnership with VBI Vaccines Inc. to advance the development of multivalent coronavirus vaccines that could be deployed against COVID-19 and possible future coronaviruses with pandemic potential, referred to as coronavirus X.
Abbvie Inc. and Hotspot Therapeutics Inc. have entered into an exclusive worldwide collaboration and option to license agreement for Hotspot's discovery-stage interferon regulatory factor 5 (IRF5) program for the treatment of autoimmune diseases.
Tonix Pharmaceuticals Holding Corp. has entered into a sponsored research agreement with Boston Children's Hospital to study TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, for the prevention of graft-vs.-host disease (GVHD) after hematopoietic stem cell transplant (HSCT) in animals.
Eikonoklastes Therapeutics Inc. and Forge Biologics Inc. have established a manufacturing partnership to advance Eikonoklastes' adeno-associated viral (AAV)-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Umoja Biopharma Inc. and Nanjing Iaso Biotherapeutics Co. Ltd. have entered into a research agreement to evaluate Umoja's ICIL (induced cytotoxic innate lymphocytes) platform with Iaso's best-in-class chimeric antigen receptors (CARs).
Sensei Biotherapeutics Inc. has entered into a sponsored research agreement with Washington University in St. Louis to support development of SNS-101, a conditionally active V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA)-blocking antibody.
RSS
